Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Structure Therapeutics Inc. - American Depositary Shares (NQ:GPCR)

66.55 -0.92 (-1.36%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 20, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 940,481
Open 67.11
Bid (Size) 66.55 (3,400)
Ask (Size) 66.59 (100)
Prev. Close 67.47
Today's Range 65.58 - 68.14
52wk Range 13.22 - 94.90
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
The Trillion-Dollar Pharmaceutical Giant: Eli Lilly Makes History as Weight-Loss Revolution Drives Unprecedented Growth
In a historic moment for the global healthcare industry, Eli Lilly and Company (NYSE:LLY) has officially cemented its position as the world’s first pharmaceutical company to surpass a $1 trillion... 
Via MarketMinute
Topics Earnings Economy
News headline image
Structure Therapeutics Stock Up 187% in One Year as Fund Trims $8 Million From Stake ↗
Structure Therapeutics develops oral therapies for chronic diseases, using a proprietary platform to target G-protein-coupled receptors. 
Via The Motley Fool

Performance

YTD
-2.3%
-2.3%
1 Month
-26.9%
-26.9%
3 Month
+93.8%
+93.8%
6 Month
+243.6%
+243.6%
1 Year
+179.0%
+179.0%

More News

Read More
News headline image
Eli Lilly Projects Record $80B-$83B Revenue for 2026 as Metabolic Franchise Decouples from Competition
Via MarketMinute
Topics Earnings Economy
VKTX, TERN, GPCR Shares Rally As Novo Nordisk Sounds Willingness Towards Portfolio-Expansion Deals ↗
Via Stocktwits
News headline image
This Healthcare Company Believes Its GLP-1 Pill Could Be "Next in Line" After Novo Nordisk and Eli Lilly. Its Valuation Is a Fraction of Theirs. ↗
Via The Motley Fool
News headline image
A 10% Owner Of Structure Therapeutics Shed Shares ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Can This Stock Double Again in 2026? ↗
Via The Motley Fool
News headline image
The 2026 Pharma M&A Outlook: Obesity, HIV, and the Biotech Renaissance
Via MarketMinute
Topics Artificial Intelligence Economy Intellectual Property
Why Did Structure Therapeutics Stock Surge Pre-Market Today? ↗
Via Stocktwits
News headline image
Hims & Hers Enters 2026 On Solid Ground — Stock Rises Even After Novo Nordisk Leaves It Off Wegovy Partner List ↗
Via Stocktwits
News headline image
Biotech’s Resurgence: How a Year-End Rally and M&A Frenzy Set the Stage for 2026
Via MarketMinute
Topics Artificial Intelligence ETFs Economy
News headline image
The Case for Small-Cap Diversification: Why Investors are Looking Beyond Mega-Cap Tech
Via MarketMinute
Topics Artificial Intelligence Economy
News headline image
Novo Nordisk Breaks the Mold: Oral Obesity Breakthrough Sends Shares to New Heights as Pharma Landscape Shifts
Via MarketMinute
Topics Economy
News headline image
The Great Rotation: Small-Caps Seize the Spotlight as Mega-Cap Fatigue Sets In
Via MarketMinute
Topics Economy
News headline image
The Great Rotation: Small-Cap Growth Surges as Investors Ditch Defensive Safety for Post-Fed Gains
Via MarketMinute
Topics Artificial Intelligence ETFs Economy
News headline image
The Great Rotation: Small-Caps Break Out as Russell 2000 Hits Record Highs in Late 2025
Via MarketMinute
Topics Artificial Intelligence ETFs Economy
News headline image
Structure Therapeutics Announces Initiation of Phase 1 Clinical Study of Oral Small Molecule Amylin Receptor Agonist ACCG-2671 for the Treatment of Obesity
From Structure Therapeutics Inc.
Via GlobeNewswire
News headline image
Structure Therapeutics Announces Closing of Upsized $747.5 Million Public Offering of ADSs and Pre-Funded Warrants and Full Exercise of the Underwriters’ Option to Purchase Additional ADSs
From Structure Therapeutics Inc.
Via GlobeNewswire
News headline image
Structure Therapeutics Announces Pricing of Upsized $650 Million Public Offering of ADSs and Pre-Funded Warrants
From Structure Therapeutics Inc.
Via GlobeNewswire
News headline image
Why Structure Therapeutics Stock Doubled and Then Some on Monday ↗
Via The Motley Fool
News headline image
Global Markets Brace for Fed Decision Amidst Divergent Policies and Geopolitical Crosscurrents
Via MarketMinute
Topics Artificial Intelligence Bonds Economy
News headline image
Structure Therapeutics Announces Proposed $500 Million Public Offering of American Depositary Shares and Pre-Funded Warrants
From Structure Therapeutics Inc.
Via GlobeNewswire
News headline image
What's going on in today's session ↗
Via Chartmill
News headline image
Wondering what's happening in today's pre-market session? ↗
Via Chartmill
News headline image
Structure Therapeutics Reports Positive Topline Data from ACCESS Program for its Once-Daily Oral Small Molecule GLP-1 Receptor Agonist, Aleniglipron
From Structure Therapeutics Inc.
Via GlobeNewswire

Frequently Asked Questions

Is Structure Therapeutics Inc. - American Depositary Shares publicly traded?
Yes, Structure Therapeutics Inc. - American Depositary Shares is publicly traded.
What exchange does Structure Therapeutics Inc. - American Depositary Shares trade on?
Structure Therapeutics Inc. - American Depositary Shares trades on the Nasdaq Stock Market
What is the ticker symbol for Structure Therapeutics Inc. - American Depositary Shares?
The ticker symbol for Structure Therapeutics Inc. - American Depositary Shares is GPCR on the Nasdaq Stock Market
What is the current price of Structure Therapeutics Inc. - American Depositary Shares?
The current price of Structure Therapeutics Inc. - American Depositary Shares is 66.55
When was Structure Therapeutics Inc. - American Depositary Shares last traded?
The last trade of Structure Therapeutics Inc. - American Depositary Shares was at 02/20/26 04:00 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

© Copyright 2015, Penticton Herald, Penticton, BC. Powered by BLOX Content Management System from TownNews.com.